OrthoPediatrics, a pediatric orthopedics company, announced its financial results for the second quarter 2Q, which ended June 30.
Business and Financial Highlights:
- Generated new record high total revenue of $61.1 million for 2Q, up 16 percent from $52.8 million in second quarter 2024; domestic revenue increased 17 percent and international revenue increased 12 percent in the second quarter
- Grew worldwide trauma and deformity revenue 10 percent and worldwide scoliosis revenue 35 percent in 2Q 2025 compared to 2Q 2024
- Increased adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) by 58 percent to $4.1 million in 2Q 2025, compared to $2.6 million in 2Q 2024
- Gross profit for 2Q 2025 was $44.0 million, an 8 percent increase compared to $40.8 million for the same period last year. Gross profit margin for 2Q 2025 was 72 percent, compared to 77 percent for the same period last year.
- Total operating expenses for 2Q 2025 were $54.7 million, an 18 percent increase compared to $46.5 million for the same period last year
- Sales and marketing expenses increased $2.5 million, or 15 percent, to $19.1 million in the first quarter of 2025
- Research and development expenses decreased $0.4 million, or 15 percent, to $2.2 million in the first quarter of 2025
- General and administrative expenses increased $3.1 million, or 11 percent, to $30.4 million in the first quarter of 2025.
- Expanded the OrthoPediatrics Bracing Division with multiple new clinics and entry into two new territories, including its first international operation in Ireland.
- Increased full year 2025 revenue guidance to a range of $237 million to $242 million from a range of $236 million to $242 million, representing growth of 16 percent to 18 percent compared to prior year
